Immunogenicity After COVID-19 Vaccines in Adapted Schedules

Conditions: Coronavirus Disease 2019; COVID-19 Interventions: Drug: BNT162b2 30 µg; Drug: BNT162b2 20µg; Drug: BNT162b2 6µg; Drug: mRNA-1273 100µg; Drug: mRNA-1273 50µg; Drug: ChAdOx1-S [Recombinant] Sponsors: Universiteit Antwerpen Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials